{
    "eid": "2-s2.0-85113572829",
    "title": "Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Alectinib",
        "ALK-positive",
        "Blood-based assay",
        "Next-generation sequencing",
        "NSCLC"
    ],
    "authors": [
        "Rafal Dziadziuszko",
        "Tony Mok",
        "Solange Peters",
        "Ji Youn Han",
        "Jorge Alatorre-Alexander",
        "Natasha Leighl",
        "Virote Sriuranpong",
        "Maurice P\u00e9rol",
        "Gilberto de Castro Junior",
        "Ernest Nadal",
        "Filippo de Marinis",
        "Osvaldo Ar\u00e9n Frontera",
        "Daniel S.W. Tan",
        "Dae Ho Lee",
        "Hye Ryun Kim",
        "Mark Yan",
        "Todd Riehl",
        "Erica Schleifman",
        "Sarah M. Paul",
        "Simonetta Mocci",
        "Rajesh Patel",
        "Zoe June Assaf",
        "David S. Shames",
        "Michael S. Mathisen",
        "Shirish M. Gadgeel"
    ],
    "citedby-count": 19,
    "ref-count": 28,
    "ref-list": [
        "Non-small cell lung cancer, version 4.2021",
        "Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology",
        "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated September 2020",
        "Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer",
        "Liquid biopsy as surrogate to tissue in lung cancer for molecular profiling: a meta-analysis",
        "Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer",
        "Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)",
        "Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer",
        "Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer",
        "Liquid biopsies: genotyping circulating tumor DNA",
        "Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy",
        "Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab",
        "Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA",
        "Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin",
        "ALK-rearrangement in non-small-cell lung cancer (NSCLC)",
        "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer",
        "Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. 1484PD (updated data presented)",
        "Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer",
        "Efficacy of ALK inhibitors on NSCLC brain metastases: a systematic review and pooled analysis of 21 studies",
        "Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study",
        "Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study",
        "Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer",
        "Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study",
        "The role of the liquid biopsy in decision-making for patients with non-small cell lung cancer",
        "Outcomes according to ALK status determined by central immunohistochemistry or fluorescence in situ hybridization in patients with ALK-positive NSCLC enrolled in the phase 3 ALEX study",
        "RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance",
        "Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer",
        "TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seoul",
            "@id": "60115402",
            "affilname": "Yonsei Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115402",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Goyang",
            "@id": "60068716",
            "affilname": "National Cancer Center, Gyeonggi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068716",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Detroit",
            "@id": "60030704",
            "affilname": "Henry Ford Health System",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030704",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60030442",
            "affilname": "Istituto Europeo di Oncologia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030442",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60027817",
            "affilname": "Princess Margaret Cancer Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027817",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "60026209",
            "affilname": "Genentech, Inc",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026209",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lausanne",
            "@id": "60023561",
            "affilname": "Centre Hospitalier Universitaire Vaudois",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023561",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Lyon",
            "@id": "60018084",
            "affilname": "Le Centre R\u00e9gional de Lutte Contre le Cancer L\u00e9on B\u00e9rard",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018084",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Hospitalet de Llobregat",
            "@id": "60015633",
            "affilname": "Institute Catala Oncologia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015633",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Gda\u0144sk",
            "@id": "60012383",
            "affilname": "Gdanski Uniwersytet Medyczny",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012383",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Sao Paulo",
            "@id": "60008088",
            "affilname": "Universidade de S\u00e3o Paulo",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008088",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60006240",
            "affilname": "University of Ulsan College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002798",
            "affilname": "Chinese University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Mexico City",
            "@id": "124797096",
            "affilname": "Health Pharma Professional Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/124797096",
            "affiliation-country": "Mexico"
        },
        {
            "affiliation-city": "Santiago",
            "@id": "121490051",
            "affilname": "Centro de Investigaci\u00f3n Cl\u00ednica Bradford Hill",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121490051",
            "affiliation-country": "Chile"
        },
        {
            "affiliation-city": "Mississauga",
            "@id": "100363548",
            "affilname": "Hoffmann-La Roche Ltd",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100363548",
            "affiliation-country": "Canada"
        }
    ],
    "funding": [
        "ACEA Pharma",
        "Alpha Biopharma Co. Ltd.",
        "Amoy Diagnostics Co. Ltd.",
        "Aurora Tele-Oncology Ltd.",
        "Biodesix",
        "Hengrui Therapeutics Inc.",
        "Hutchison Chi-Med",
        "Ignyta Inc.",
        "Liangyihui Network Technology Co. Ltd.",
        "Lunit USA Inc.",
        "Menarini",
        "Phosplatin Therapeutics",
        "Roche Ltd.",
        "Roche Ltd., Merck, Sharp & Dohme",
        "SFJ Pharmaceuticals",
        "SFJ Pharmaceuticals Ltd.",
        "Sanomics Ltd.",
        "Seattle Genetics, Foundation Medicine, and Takeda",
        "Shanghai BeBirds Translation & Consulting Co. Ltd.",
        "Boehringer Ingelheim",
        "Amgen",
        "Bristol-Myers Squibb",
        "Eli Lilly",
        "Pfizer",
        "AstraZeneca",
        "Genentech",
        "GlaxoSmithKline",
        "Merck",
        "Novartis",
        "Roche",
        "Sanofi-Aventis",
        "Merck Serono",
        "Teva",
        "AbbVie",
        "F. Hoffmann-La Roche Ltd.",
        "Takeda",
        "Janssen",
        "Merck Sharp & Dohme",
        "Clovis Oncology",
        "Bayer",
        "Mirati Therapeutics Inc.",
        "Incyte Corporation",
        "Puma Biotechnology Inc.",
        "G1 Therapeutics",
        "Daiichi Sankyo"
    ]
}